Comunidad Madrid

The Department of Science, Universities and Innovation of the Community of Madrid, has held a meeting with INMUNOTEK to evaluate the industrial doctorate program. This program is an initiative of the executive of the Community of Madrid to promote public-private collaboration through the completion of doctoral theses in an academic and business environment.

cepyme500 2020

INMUNOTEK listed in CEPYME500, 2020 edition. This is an initiative of CEPYME (State Confederation of Small and Medium Enterprises) to identify, recognize and support the 500 leading companies in business growth in Spain. INMUNOTEK was already listed in 2017.

EPO

The European Patent Office has granted to INMUNOTEK the patent EP2982381B1. This refers to hypoallergenic neoglycoconjugates performed with non-oxidized mannan derived from S. cerevisiae to be used for the development of novel allergy vaccines targeting dendritic cells.

Sello IeE

INMUNOTEK obtains the CIEGE Seal for excellence in business management for the second consecutive year. This Seal certifies excellent management over 57 indicators from 10 categories: solvency, profitability, growth, employment, internationalization, corporate social responsibility, customer satisfaction, innovation, commercial risk management and digitization.

Ministerio

The Spanish Ministry of Science and Innovation has granted the RETOS-Collaboration RTC2019-007097-1 project submitted by INMUNOTEK and the Complutense University of Madrid for the development of new vaccines for the treatment of food allergies. The approved project will experimentally address different vaccine prototypes against the main allergy-causing foods.

logo PNID2

The Spanish Ministry of Science, Innovation and Universities has awarded INMUNOTEK the National Innovation Award 2019. This price, the highest award granted in Spain to distinguish companies that make innovation their main business growth strategy, is endowed with 30,000 euros and has been granted to INMUNOTEK in the category of “Small and Medium-Sized Enterprise”.

Patente EEUU

The US Patent Office has granted the patent US9901633B2 to INMUNOTEK. This refers to new glycoconjugates performed with non-oxidized mannan derived from S. cerevisiae that can be used for designing novel vaccines targeting dendritic cells. This approach is being used for the development of allergy vaccines with improved immunomodulatory properties.

Empresa Innovadora

Inc. magazine revealed the 2018 Inc. 5000 list of fastest-growing private companies in Europe.  With an accumulated growth of more than 80%, INMUNOTEK has made into this ranking.